A Controlled Study of 2 Doses of Idebenone in the Treatment of Alzheimer’s Disease

Weyer, G., Babej-Dölle, R.M., Hadler, D., Hofmann, S., Herrmann, W.M.·2008·Neuropsychobiology
DOI 10.1159/000119366

Cited by (121)

Items 101–121 of 121

  1. Coenzyme Q and Age-Related Neurodegenerative Disorders: Parkinson and Alzheimer Diseases
    Francisco Javier Alcain, Javier Domínguez, Mario Durán‐Prado, Julia Vaamonde · 2020 · Springer eBooks
  2. The role of mitochondrial dysfunction in Alzheimer’s disease
    N. N. Koberskaya · 2019 · Meditsinskiy sovet = Medical Council
  3. Advances in Methodology and Current Prospects for Primary Drug Therapies for Alzheimer's Disease
    David S. Knopman · 2003 · Humana Press eBooks
  4. Potential Therapies for Mitochondrial Dysfunction
    Claire Henchcliffe, M. Flint Beal · 2011 · Springer eBooks
  5. Idebenone for the treatment of Duchenne muscular dystrophy
    Jinsong Geng, JianCheng Dong, Kui Jiang · 2010 · Cochrane Database of Systematic Reviews
  6. Role of Environmental and Inflammatory Toxicity in Neuronal Cell Death
    Mallika Somayajulu‐Nitu, Danijela Domazet-Damjanov, Anca Matei, Edward Schwartzenberger, Jerome S. Cohen, Siyaram Pandey · 2008 · The Open Toxicology Journal
  7. Anti-inflammatory and Antioxidant Therapies in Alzheimer's Disease
    Paul S. S. Aisen, Giulio Maria Pasinetti · 2001 · Elsevier eBooks
  8. Treatment of Alzheimer's Disease (With or Without Cerebrovascular Disease)
    Lon S. Schneider, Nawab Qizilbash, Mary C. Sano, Fadi Massoud, Jeffrey Alan Kaye, Jason T. Olin, Knut Laake, Anne Rita Øksengaard, Barry Oken, Kristine S. Yaffe et al. · 2003 · Wiley eBooks
  9. Cognitive Enhancers and Treatments for Alzheimer's Disease
    D. P. Devanand · 2015 · Wiley eBooks
  10. Drugs in Development and Experimental Approaches
    Murat Emre · 2003 · Wiley eBooks
  11. Ansätze zur Frühbehandlung bei degenerativen Hirnerkrankungen
    Karl Herholz · 1998 · Springer eBooks
  12. How to use cerebral vasodilators and metabolic activators.
    Kazuo Isozumi, Yoshio Izumi · 1998 · PubMed
  13. Alzheimer's disease, which is characterized by progressive loss of memory and cognitive function, affects 15 million people worldwide. Mayeux and Sano examine some of the current treatments for this devastating disease.
    Richard P Mayeux · 2006
  14. The Potential Application of Antioxidant Agents in Alzheimer Disease Therapeutics
    Paula Isabel Moreira, Mark A. Smith, Xiongwei Zhu, Akihiko Nunomura, George L. Perry · 2007 · Springer eBooks
  15. Research Priorities for Complementary Medicine in Australia
    Alan Bensoussan · 2013
  16. [Cerebral ischemic malacia. A retrospective study of CAT scan-documented cases].
    Paolo Bottoni, L Bobba, Luigi Ricordi, C Formaini, Lorenzo Preda, Marco Rollone · 1989 · PubMed
  17. Idebenone for the treatment of Duchenne muscular dystrophy
    Jinsong Geng, JianCheng Dong, Kui Jiang · 2012 · Cochrane Database of Systematic Reviews
  18. I
    Franz von Bruchhausen, E. Hackenthal, Siegfried Ebel et al. · 1999 · Springer eBooks
  19. Ferroptosis Modulators: A Potential Therapeutic Target in Alzheimer’s Disease
    Gourav Singh, Nishant Kumar Rana, Indubhusan Mishra, Gyan Prakash Modi · 2023 · Springer eBooks
  20. The Substrate-Engine Model of Ferroptosis: Stage-Specific Targeting of Acyl-CoA Synthetase Long-Chain Family Member 4 and 5-Lipoxygenase in Alzheimer’s Disease
    Anay Mondal, Reetuparna Acharya, Smita Jain · 2026 · ACS Pharmacology & Translational Science
  21. Monitoreo de la actividad despigmentante de la idebenoma
    Martin Laguens, G. Zeitune, M. Reigosa, J. Cebrián, V. Labarta, N. Almiñana · 2008 · Revista Medicina Cutánea Ibero-Latino-Americana